21
points
AI-powered drug discovery for aging — which companies to watch?
The intersection of AI and longevity research is heating up. Insilico Medicine, Calico, and several smaller startups are using ML to identify new targets. Has anyone been following this space closely? I'm particularly interested in companies that are targeting fundamental aging hallmarks rather than individual diseases.
Comments
Log in to join the discussion.
Calico has been disappointing honestly. Google money and 10 years of work with very little to show in terms of clinical pipeline.
Insilico is the furthest along — they have drug candidates in Phase 2 that were entirely AI-discovered. Their anti-fibrosis compound looks promising.
Keep an eye on Recursion Pharmaceuticals. Their whole-cell phenotypic screening + ML approach is really powerful.